Company intelligence / Profile preview

IVT Imuno

Halifax, Nova Scotia, Canadaivtimuno.com ↗

Ownership: Private
Development stage: Commercial

Overview

ImmunoVaccine Technologies developed a patented vaccine delivery platform called VacciMax®, designed to enhance immune responses for both therapeutic and preventive vaccines. The company reported positive preclinical results and initiated early clinical studies targeting cancers such as cervical, breast, prostate, colon melanoma as well as infectious diseases like influenza. They licensed several tumor antigens from Immunotope Inc., expanded their patent portfolio internationally, and scaled up manufacturing processes by 2007–2009. No recent clinical results are available after this period.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineBiologic
Industry: Biotech

Partnerships

Exclusive licensing agreement with Immunotope Inc. for seven cancer antigens.

Beyond the preview

Go deeper on IVT Imuno.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVT Imuno.

Explore the full profile